Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective

Immune checkpoint inhibitors (CPIs) are an effective treatment for many cancers but cause diverse immune-related adverse events (IrAEs). Rheumatological IrAEs include arthralgia, arthritis, tenosynovitis, myositis, polymyalgia rheumatica and sicca syndrome. CPI use can unmask RA as well as causing f...

Descripción completa

Detalles Bibliográficos
Autores principales: Steven, Neil M, Fisher, Benjamin A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900910/
https://www.ncbi.nlm.nih.gov/pubmed/31816079
http://dx.doi.org/10.1093/rheumatology/kez536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900910/
https://www.ncbi.nlm.nih.gov/pubmed/31816079
http://dx.doi.org/10.1093/rheumatology/kez536

Ejemplares similares